Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.…
COLL or SDZNY: Which Is the Better Value Stock Right Now?
Sandoz Group (SWX: SDZ) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 20,000 employees.
The shares were at 80.50 CHF on 20 November 2026, up 51.2% over 52 weeks. Its 52-week range is 52.54 CHF to 86.90 CHF: the price is 7.4% below the high and 53.2% above the low.
At a market capitalisation of 34.83B CHF, it trades at 68.8 times trailing earnings and 20.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 181% for SDZ. It pays a dividend yielding 0.98% (it pays out 68% of its earnings), against a median of 2.04% among the dividend payers in that peer group.
Sandoz Group reports return on equity of 9.7%, an operating margin of 9.3% and revenue up 9.9% year over year.
Its debt exceeds its cash by 3.93B USD, a debt-to-equity ratio of 0.61. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 16 analysts cover the stock, with an average rating of Hold; their mean price target of 81.33 CHF is 1.0% above the current price. The next earnings report is expected on 17 February 2027.